LGM
BCYC

Logos Global Management’s Bicycle Therapeutics BCYC Stock Holding History

Logos Global Management’s Portfolio BCYC Stock Details BCYC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-500,000
Closed -$11.3M – 51
2024
Q3 		$11.3M Buy
+500,000
New +$11.5M 1.22% 28
2023
Q3 		– Sell
-520,000
Closed -$13.3M – 59
2023
Q2 		$13.3M Sell
520,000
-230,000
-31% -$5.34M 1.81% 19
2023
Q1 		$16M Sell
750,000
-685,000
-48% -$17.2M 2.28% 17
2022
Q4 		$42.5M Sell
1,435,000
-565,000
-28% -$15.2M 4.98% 6
2022
Q3 		$46.5M Buy
2,000,000
+300,000
+18% +$7.14M 5.72% 6
2022
Q2 		$28.5M Buy
1,700,000
+750,000
+79% +$15.8M 5.23% 7
2022
Q1 		$41.7M Buy
950,000
+80,000
+9% +$3.74M 5.4% 8
2021
Q4 		$53M Sell
870,000
-605,000
-41% -$33.4M 5.46% 4
2021
Q3 		$61.3M Buy
1,475,000
+760,000
+106% +$26.6M 4.42% 4
2021
Q2 		$21.7M Sell
715,000
-85,000
-11% -$2.57M 1.82% 21
2021
Q1 		$23.9M Buy
+800,000
New +$20.6M 2.33% 12

Other funds holding BCYC

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
FIS
FCPM III Services Naarden, Netherlands $722M AUM 73.61% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
TCM
Tybourne Capital Management Hong Kong $30.9M AUM 20.1% 1-Year Est. Return
BNP Paribas Asset Management
BNP Paribas Asset Management Paris, France $86.1B AUM 29.11% 1-Year Est. Return

Logos Global Management's BCYC Position: Q4 2024 in Review

Logos Global Management sold out of Bicycle Therapeutics (BCYC) in Q4 2024, closing a stake of 500,000 shares — an estimated $11.3M sold.

Logos Global Management first reported a position in BCYC in Q1 2021 and held it in 11 quarters. The position peaked at $61.3M in Q3 2021. 97 funds tracked by Wall St. Rank hold BCYC as of Q4 2024.

  • Logos Global Management reported no remaining Bicycle Therapeutics position as of Q4 2024 after selling out during the quarter.
  • Logos Global Management sold 500,000 Bicycle Therapeutics shares in Q4 2024, an estimated $11.3M.
  • Logos Global Management first reported a position in Bicycle Therapeutics in Q1 2021 and held it in 11 quarters.
  • Logos Global Management's Bicycle Therapeutics position peaked at $61.3M in Q3 2021.
  • 97 funds tracked by Wall St. Rank held Bicycle Therapeutics as of Q4 2024.

Based on Logos Global Management's 13F filing for Q4 2024, filed 14 Feb 2025.